Phase II Trial: uPAR-PET/CT for Prognostication in Head- and Neck Cancer
NCT02965001
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
57
Enrollment
OTHER
Sponsor class
Conditions
Head and Neck Cancer
Interventions
DRUG:
68Ga-NOTA-AE105
Sponsor
Rigshospitalet, Denmark